Kohmer 2021 [B].

Study characteristics
Patient Sampling	Comparative study of 4 Ag tests; Kohmer 2021 [A] reports full study characteristics and QUADAS.
Patient characteristics and setting	Comparative study of 4 Ag tests; Kohmer 2021 [A] reports full study characteristics and QUADAS.
Index tests	Test name: [A] RIDA QUICK SARS‐CoV‐2 Antigen [B] SARS‐CoV‐2 Rapid Antigen Test [C] NADAL COVID‐19 Ag Test (test cassette) [D] SARS‐CoV‐2 Ag Test on the LumiraDx Platform Manufacturer: [A] R‐Biopharm AG, Darmstadt, Germany [B] Roche Diagnostics GmbH, Mannheim, Germany [C] Nal von Minden GmbH, Regensburg, Germany [D] LumiraDx GmbH, Cologne, Germany Antibody: not stated Ag target: not stated Test method: [A], [B], [C] not stated [D] immunofluorescence assay Samples used: NP Transport media: PBS Sample storage: sample storage not stated; tested within 24 h after collection Test operator: not stated Definition of test positivity: for [A], [B], [C] the results were read visually and documented by 3different individuals, and the majority consensus was chosen as the final test result; Not stated for [D] (IFU indicates that a reader device is required) Blinding reported: unclear; parallel testing Timing of samples: not stated
Target condition and reference standard(s)	Comparative study of 4 Ag tests; Kohmer 2021 [A] reports full study characteristics and QUADAS.
Flow and timing	Comparative study of 4 Ag tests; Kohmer 2021 [A] reports full study characteristics and QUADAS.
Comparative
Notes	Comparative study of 4 Ag tests; Kohmer 2021 [A] reports full study characteristics and QUADAS.